妊娠期肝内胆汁淤积症的研究进展

摘要/Abstract

摘要： 妊娠期肝内胆汁淤积症(ICP)是妊娠中晚期常见的并发症。近年研究提示,肠道菌群失衡在ICP的发生和发展过程中发挥了重要作用。ICP可增加妊娠合并症的发生率,如子痫前期、妊娠期糖尿病等,对胎儿造成不良影响;ICP孕妇血清胆汁酸谱分析有助于临床诊断和鉴别诊断;熊去氧胆酸仍然是ICP一线治疗药物,奥贝胆酸是很有潜力的一种药物。

李菊红, 邵勇. 妊娠期肝内胆汁淤积症的研究进展[J]. 肝脏, 2024, 29(3): 348-351.

[1] Zhan Q, Qi X, Weng R, et al. Alterations of the human gut microbiota in intrahepatic cholestasis of pregnancy[J]. Front Cell Infect Microbiol, 2021, 11: 635680.
[2] Tang B, Tang L, Li S, et al. Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy[J]. Nat Commun, 2023, 14(1):1305.
[3] Fang D, Fang Y, Zhang W, et al. Comprehensive analysis of quantitative proteomics with DIA mass spectrometry and ceRNA network in intrahepatic cholestasis of pregnancy[J]. Front Cell Dev Biol, 2022, 10:854425.
[4] Shan D, Dong R, Hu Y. Current understanding of autophagy in intrahepatic cholestasis of pregnancy[J]. Placenta, 2021, 115:53-59.
[5] Beuers U, Wolters F, Oude Elferink R P J. Mechanisms of pruritus in cholestasis: understanding and treating the itch[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1):26-36.
[6] Kremer A E, Martens J J, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus[J]. Gastroenterology, 2010, 139(3):1008-1018, 1018.e1.
[7] Yu H, Wangensteen K, Deng T, et al. MRGPRX4 in cholestatic pruritus[J]. Semin Liver Dis, 2021, 41(3):358-367.
[8] Mor M, Shmueli A, Krispin E, et al. Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia[J]. Arch Gynecol Obstet, 2020, 301(3):655-664.
[9] Perino A, Demagny H, Velazquez-Villegas L, et al. Molecular physiology of bile acid signaling in health, disease, and aging[J]. Physiol Rev, 2021, 101(2):683-731.
[10] De Vivo A, Baviera G, Giordano D, et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia[J]. Acta Obstet Gynecol Scand, 2008, 87:837-842.
[11] Li H, Gu B, Zhang Y, et al. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta[J]. Placenta, 2005, 26:210-217.
[12] Perez M J, Briz O. Bile-acid-induced cell injury and protection[J]. World J Gastroenterol, 2009,15(14): 1677-1689.
[13] Zhang L, Tang C, Ye C, et al. Intrahepatic cholestasis of pregnancy can increase the risk of metabolic disorders: a meta-analysis[J]. J Med Biochem, 2022, 41(4):549-558.
[14] Mashburn S, Schleckman E, Cackovic P, et al. Intrahepatic cholestasis of pregnancy: risk factors for severe disease[J]. J Matern Fetal Neonatal Med, 2022, 35(25):8566-8570.
[15] Fiorucci S, Mencarelli A, Palladino G, et al. Bile-acidactivated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders[J]. Trends Pharmacol Sci, 2009, 30:570-580.
[16] Martineau M G, Raker C, Dixon P H, et al. The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dyslipidemia, and increased fetal growth[J]. Diabetes Care, 2015, 38:243-248.
[17] Bellafante E, McIlvride S, Nikolova V, et al. Maternal glucose homeostasis is impaired in mouse models of gestational cholestasis[J]. Sci Rep, 2020, 10(1):11523.
[18] Marschall H U, Wikstrom Shemer E, Ludvigsson J F, et al. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study[J]. Hepatology, 2013, 58(4): 1385-1391.
[19] Wikström Shemer E A, Stephansson O, Thuresson M, et al. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovas-cular diseases: a population-based cohort study[J]. J Hepatol, 2015, 63(2):456-461.
[20] Geenes V, Chappell L C, Seed P T, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study[J]. Hepatology, 2014, 59: 1482-1491.
[21] Arthuis C, Diguisto C, Lorphelin H, et al. Perinatal outcomes of intrahepatic cholestasis during pregnancy: an 8-year case-control study[J]. PLoS One, 2020, 15(2):e0228213.
[22] Sarker M, Zamudio A R, DeBolt C, et al. Beyond stillbirth: association of intrahepatic cholestasis of pregnancy severity and adverse outcomes[J]. Am J Obstet Gynecol, 2022, 227(3): 517.e1-517.e7.
[23] Ovadia C, Seed P T, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahe-patic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses[J]. Lancet, 2019, 393(10174):899-909.
[24] Herraez E, Lozano E, Poli E, et al. Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis[J]. J Mol Med (Berl), 2014, 92:359-372.
[25] Perez M J, Macias R I, Duran C, et al. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid[J]. J Hepatol, 2005,43:324-332.
[26] Šimják P,Parízek A,Vítek L,et al.Fetal complications due to intrahepatic cholestasis of pregnancy[J]. J Perinat Med, 2015, 43(2):133-139.
[27] Vasavan T, Deepak S, Jayawardane I A, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations[J]. J Hepatol, 2021, 74:1087-1096.
[28] Smith D D, Rood K M, Rood K M. Intrahepatic cholestasis of pregnancy[J]. Clin Obstet Gynecol, 2020,63(1):134-151.
[29] Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy[J]. World J Gastroenterol, 2009, 15(17): 2049-2066.
[30] Zecca E, Costa S, Lauriola V, et al. Bile acid pneumonia: a "new" form of neonatal respiratory distress syndrome?[J]. Pediatrics, 2004, 114:269-272.
[31] Walker I A, Nelson-Piercy C, Williamson C. Role of bile acid measurement in pregnancy[J]. Ann Clin Biochem, 2002, 39:105-113.
[32] Shao Y, Chen S, Li H, et al. Maternal bile acid profile and subtype analysis of intrahepatic cholestasis of pregnancy[J]. Orphanet J Rare Dis, 2021, 16(1): 259.
[33] Ma Z, Liu Y, Chai L, et al. Metabolic changes in bile acids with pregnancy progression and their correlation with perinatal complications in intrahepatic cholestasis of pregnant patients[J]. Sci Rep, 2023, 13(1):1608.
[34] Li Y, Zhang X, Chen J, et al. Targeted metabolomics of sulfated bile acids in urine for the diagnosis and grading of intrahepatic cholestasis of pregnancy[J]. Genes Dis, 2018, 5(4):358-366.
[35] ACOG committee opinion no. 764: medically indicated late-preterm and early-term deliveries[J]. Obstet Gynecol, 2019, 133(2): e151-e155.
[36] Kong X, Kong Y, Zhang F Y, et al. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: a meta-analysis (a prisma-compliant study)[J]. Medicine (Baltimore), 2016, 95(40):e4949. Erratum in: Medicine (Baltimore), 2017, 96(3):e6031.
[37] Chappell L C, Bell J L, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial[J]. Lancet, 2019, 394(10201):849-860.
[38] Hagenbeck C, Pecks U, Lammert F, et al. Intrahepatic cholestasis of pregnancy[J]. Gynakologe, 2021,54(5):341-356.
[39] Roy A, Premkumar M, Mishra S, et al. Role of ursodeoxycholic acid on maternal serum bile acids and perinatal outcomes in intrahepatic cholestasis of pregnancy[J]. Eur J Gastroenterol Hepatol, 2021, 33(4):571-576.
[40] Keitel V, Dröge C, Häussinger D. Targeting FXR in Cholestasis[J]. Handb Exp Pharmacol, 2019, 256: 299-324.
[41] Anakk S, Watanabe M, Ochsner SA, et al. Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis[J]. J Clin Invest, 2022, 121(1):86-95.
[42] Krupa K, Hapshy V, Nguyen H, et al. Obeticholic Acid. 2022 Dec 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing,2022.
[43] Pataia V, McIlvride S, Papacleovoulou G, et al. Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(2): G197-G211.
[44] Lee R H, Mara G, Metz T D, et al. Society for maternal-fetal medicine consult series #53: intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011[J]. Am J Obstet Gynecol, 2021, 224(2): B2-B9.
[45] Girling J, Knight C L, Chappell L, et al. Intrahepatic cholestasis of pregnancy: green-top guideline No. 43 June 2022[J]. BJOG, 2022, 129(13): e95-e114.

妊娠期肝内胆汁淤积症的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许宏辉, 付旭峰, 印永祥, 赵军, 贾笑天, 孙敏雅, 张岩. HBV感染孕妇早期胆汁酸谱检测在妊娠期肝内胆汁淤积症诊断中的应用[J]. 肝脏, 2024, 29(3): 327-331.
[2]	陈玲燕, 刘嘉玉, 李京阳, 顾颖, 张岩. 氧化应激与妊娠期肝内胆汁淤积症相关性研究进展[J]. 肝脏, 2023, 28(9): 1116-1118.
[3]	顾竞娴, 张英平, 徐晓英. 血清NLR、sVCAM-1和IGFBP-3水平与妊娠期肝内胆汁淤积症病情程度和疾病预后的相关性[J]. 肝脏, 2023, 28(7): 840-844.
[4]	陈文丹, 韩凤琼, 张金凤, 林悦, 郭俊豪, 宋爱峰, 潘海燕. 妊娠期肝内胆汁淤积症患者不良妊娠结局的危险因素分析[J]. 肝脏, 2023, 28(5): 576-580.
[5]	邓庆铃, 张鹏. 原发性胆汁性胆管炎的药物治疗现状及进展[J]. 肝脏, 2023, 28(2): 257-260.
[6]	吴婷, 徐晓英, 郑丽. 血清TPOAb和25-(OH)D3水平联合检测在妊娠期肝内胆汁淤积症中的临床价值[J]. 肝脏, 2022, 27(9): 1025-1029.
[7]	朱时帅, 芦曦. 肝内胆汁淤积症血清胆汁酸谱的特征及研究进展[J]. 肝脏, 2022, 27(6): 715-719.
[8]	范晶晶, 王小红. 妊娠期肝内胆汁淤积症与胎儿生长受限及不良妊娠结局的关系[J]. 肝脏, 2022, 27(2): 238-241.
[9]	龚燕, 龚杰. 妊娠期肝内胆汁淤积症的致病因素和药物治疗进展[J]. 肝脏, 2022, 27(2): 247-249.
[10]	薛魁, 石慧, 王文娟. 血清甘胆酸水平与妊娠期肝内胆汁淤积症患者不良妊娠结局的相关性[J]. 肝脏, 2021, 26(8): 920-923.
[11]	朱悦, 钱晓寒, 季国忠, 杨丽华. 血清胆汁酸谱在非酒精性脂肪性肝病患者中的表达及意义[J]. 肝脏, 2021, 26(11): 1279-1282.
[12]	张艳伟, 杨锐, 岳欣, 韩国荣, 王根菊. 肝内胆汁淤积症对妊娠期患者肝生化指标、炎性细胞因子变化及胎儿结局的影响[J]. 肝脏, 2020, 25(9): 982-985.
[13]	裴广丽, 谢洁, 刘德荣, 徐金娥. 胎盘中信号转导和转录活化因子3与妊娠期肝内胆汁淤积症患者围产结局的关系[J]. 肝脏, 2020, 25(8): 870-872.
[14]	王吕, 王惠, 汤卫春, 陆月梅. 妊娠期肝内胆汁淤积症蜕膜组织T细胞和B细胞失调与病情程度的关系[J]. 肝脏, 2020, 25(12): 1323-1325.
[15]	郑爱梅, 张四芳, 刘晓燕, 郑丽. 低分子肝素钠联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症的疗效及对母婴结局的影响[J]. 肝脏, 2020, 25(12): 1337-1339.